These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29214576)

  • 1. New Therapeutic Uses for Existing Drugs.
    Austin BA; Gadhia AD
    Adv Exp Med Biol; 2017; 1031():233-247. PubMed ID: 29214576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs.
    Kesselheim AS; Tan YT; Avorn J
    Health Aff (Millwood); 2015 Feb; 34(2):286-93. PubMed ID: 25646109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. eRepo-ORP: Exploring the Opportunity Space to Combat Orphan Diseases with Existing Drugs.
    Brylinski M; Naderi M; Govindaraj RG; Lemoine J
    J Mol Biol; 2018 Jul; 430(15):2266-2273. PubMed ID: 29237557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.
    Micallef J; Boutouyrie P; Blin O
    Fundam Clin Pharmacol; 2017 Dec; 31(6):685-694. PubMed ID: 28779530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing in rare diseases: Myths and reality.
    Fetro C; Scherman D
    Therapie; 2020 Apr; 75(2):157-160. PubMed ID: 32241561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico repositioning of approved drugs for rare and neglected diseases.
    Ekins S; Williams AJ; Krasowski MD; Freundlich JS
    Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
    Kumar Kakkar A; Dahiya N
    Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Financing drug discovery for orphan diseases.
    Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW
    Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cohorts and registers: Which public/private partnerships to choose?].
    Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
    Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantifying emerging drugs for very rare conditions.
    Miles KA; Packer C; Stevens A
    QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Participant-funded clinical trials on rare diseases].
    Dal-Ré R; Palau F; Guillén-Navarro E; Ayuso C
    An Pediatr (Engl Ed); 2020 Oct; 93(4):267.e1-267.e9. PubMed ID: 32499195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification.
    Shameer K; Readhead B; Dudley JT
    Curr Top Med Chem; 2015; 15(1):5-20. PubMed ID: 25579574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug repositioning for orphan diseases.
    Sardana D; Zhu C; Zhang M; Gudivada RC; Yang L; Jegga AG
    Brief Bioinform; 2011 Jul; 12(4):346-56. PubMed ID: 21504985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The European rare diseases therapeutic initiative.
    Fischer A; Borensztein P; Roussel C
    PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and Systems Pharmacology Approaches to Repurposing Drugs in the Wake of Global Health Burden.
    Bai JPF
    J Pharm Sci; 2016 Oct; 105(10):3007-3012. PubMed ID: 27522921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug repositioning for rare diseases: Knowledge-based success stories.
    Scherman D; Fetro C
    Therapie; 2020 Apr; 75(2):161-167. PubMed ID: 32164975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
    Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
    BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.